Existing users please login

Forgot Password

    Home / Markets / Industries / Health Care

    Wednesday, November 18, 2009

    Basilea's Cleared To Market Eczema Drug In Canada

    | Respond to Editor | Print

     
    By Robert Daniel
    MarketWatch Pulse
       

      TEL AVIV -- Basilea Pharmaceutica Ltd., the Basel drugmaker, said on Wednesday that Health Canada cleared the company to market Toctino, generically alitretinoin, to treat adults with severe chronic hand eczema whose condition hadn't responded to topical corticosteroids. Basilea is marketing the drug in Denmark, Germany and the UK and recently launched it in France. The drug has marketing clearance in a number of other European countries and has been recommended for approval in Italy, Basilea said. Eczema is a skin inflammation that causes sometimes severe itching, blisters, thickened and cracked skin, and more, the Mayo Clinic Website explains.

      Copyright © 2009 MarketWatch, Inc.

      Fox Business Video


      Last 5 Stocks

      • Ticker
      • Company
      • Price
      • Change
       

      Personal Finance - Investing - Financial News - Business News - Stock Market Quotes & News - Small Business

      Advertise with us | Jobs at FOX Business Network | Internships at FBN

      Terms of use. Privacy Statement. For FOXBusiness.com technical issues write to foxbusinessonline@foxbusiness.com; for all other feedback, write to feedback@foxbusiness.com.

      Quotes delayed at least 15 minutes. Market Data provided by Interactive Data (Terms & Conditions). Powered and implemented by Interactive Data Managed Solutions. Company fundamental data provided by Morningstar. Earnings estimates data provided by Zacks. Mutual fund data provided by Lipper. Economic data provided by Econoday. Dow Jones & Company Terms & Conditions.

      This material may not be published, broadcast, rewritten, or redistributed. ©2010 FOX News Network, LLC. All rights reserved.